Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
LXN encodes the only known protein inhibitor of zinc-dependent metallocarboxypeptidases. Zusätzlich bieten wir Ihnen Latexin Proteine (24) und Latexin Kits (4) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 171 products:
Human Polyclonal Latexin Primary Antibody für IHC, ELISA - ABIN190839
de Haan: Latexin is a newly discovered regulator of hematopoietic stem cells. in Nature genetics 2007
Show all 3 Pubmed References
Human Polyclonal Latexin Primary Antibody für IHC (p), IHC - ABIN252922
Kadouchi, Sakamoto, Tangjiao, Murakami, Kobayashi, Hoshino, Yamaguchi: Latexin is involved in bone morphogenetic protein-2-induced chondrocyte differentiation. in Biochemical and biophysical research communications 2008
Show all 2 Pubmed References
Human Polyclonal Latexin Primary Antibody für IHC - ABIN966502
Pallarès, Bonet, García-Castellanos, Ventura, Avilés, Vendrell, Gomis-Rüth: Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. in Proceedings of the National Academy of Sciences of the United States of America 2005
Human Polyclonal Latexin Primary Antibody für IHC, IHC (p) - ABIN4330408
Muthusamy, Premi, Soper, Platt, Bosenberg: The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma. in The Journal of investigative dermatology 2013
Results identified that LXN expression inversely modulates taxane-chemoresistance in the PC-3 (zeige PCSK1 Antikörper) prostate cancer cell line. Inhibition of LXN expression in the bone microenvironment promotes chemoresistance, in part through a methylation-dependent mechanism.
Results show that Lxn expression was clearly decreased in the pancreatic ductal adenocarcinoma tissues suggesting it that as a tumor suppressor that targets CD133-positive cancer cells.
Lxn protein and mRNA expression levels in CD133+ miapaca-2 cells were significantly lower than those in CD133- cells.
latexin is markedly downregulated in hepatocellular carcinoma specimens, compared to adjacent non-cancerous tissues.
CD146 (zeige MCAM Antikörper) and Lxn increased tumor migration and invasion of thyroid cancer.
The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma.
These results are consistent with a tumor suppressor role for latexin.
Latexin expression is lost or greatly reduced in approximately 50% of human leukemia/lymphoma cell lines.
By using an Lxn knockout mouse model, this study found that Lxn inactivation in vivo led to the physiological expansion of the entire hematopoietic hierarchy. Loss of Lxn enhanced the competitive repopulation capacity and survival of hematopoietic stem cells in a cell-intrinsic manner.
Rps3 (zeige RPS3 Antikörper) knockdown increased the radiation sensitivity of FDC-P1, confirming that the mechanism of action of Lxn is mediated by Rps3 (zeige RPS3 Antikörper) pathway.
Latexin is preferentially expressed in hematopoietic stem cells, and is co-localized with the molecules responsible for the interaction of hematopoietic stem cells with a bone marrow niche.
Data indicate that AAV-mediated latexin transduction or administration of a small molecule carboxypeptidase A inhibitor significantly reduced acetone-evoked nociceptive behavior after SNI.
The crystal structure of mouse latexin, solved at 1.83 A resolution, shows no structural relationship with other carboxypeptidase inhibitors.
Latexin is involved in the transmission of pain, since mice lacking this protein experience reducted pain sensitivity.
promoter polymorphisms between the B6 and D2 alleles may affect Lxn gene expression and consequently influence the population size of hematopoietic stem cells.
These results indicate that latexin is involved in BMP-2 (zeige BMP2 Antikörper)-induced chondrocyte differentiation and plays an important role in skeletogenesis and skeletal regeneration.
This gene encodes the only known protein inhibitor of zinc-dependent metallocarboxypeptidases.
, endogenous carboxypeptidase inhibitor
, tissue carboxypeptidase inhibitor